피하 투여를 위한 항-CD38 항체의 제형
항-CD38 항체의 제형을 필요로 하는 대상체에게 피하 투여하기에 적합한 항-CD38 항체의 제형이 제공된다. 본 제형은 고농도의 항체, 점도 감소제, 안정화제, 완충제 및 계면활성제를 포함한다. 특정 실시 형태에서, 용액의 점도는 최대 25 mPa·s이고, 용액의 pH는 5.9 내지 7.0이다. 특정 실시 형태에서, 항-CD38 항체는 이사툭시맙(Isatuximab)이다. 제형은 인간에서 다발성 골수종을 비롯한 CD38+ 혈액 악성종양, 및 자가면역 및 염증성 질환을 치료하는 데 사용될 것이다. Provided are formul...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | kor |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | BANGARI KIRAN FILIPE VASCO CHARI RAVI HUILLE SYLVAIN PEREZ RAMIREZ BERNARDO BALLET THOMAS |
| description | 항-CD38 항체의 제형을 필요로 하는 대상체에게 피하 투여하기에 적합한 항-CD38 항체의 제형이 제공된다. 본 제형은 고농도의 항체, 점도 감소제, 안정화제, 완충제 및 계면활성제를 포함한다. 특정 실시 형태에서, 용액의 점도는 최대 25 mPa·s이고, 용액의 pH는 5.9 내지 7.0이다. 특정 실시 형태에서, 항-CD38 항체는 이사툭시맙(Isatuximab)이다. 제형은 인간에서 다발성 골수종을 비롯한 CD38+ 혈액 악성종양, 및 자가면역 및 염증성 질환을 치료하는 데 사용될 것이다.
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_KR20220159947A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>KR20220159947A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_KR20220159947A3</originalsourceid><addsrcrecordid>eNrjZDB8O2XP26kzFN52rHkzfc3rpXsU3sxpeTt1jsLbqWt1nV2MLUCMN5u2vJk7Q-HNgjlvZ0zlYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx3kFGBkZGBoamlpYm5o7GxKkCAIXyN_U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>피하 투여를 위한 항-CD38 항체의 제형</title><source>esp@cenet</source><creator>BANGARI KIRAN ; FILIPE VASCO ; CHARI RAVI ; HUILLE SYLVAIN ; PEREZ RAMIREZ BERNARDO ; BALLET THOMAS</creator><creatorcontrib>BANGARI KIRAN ; FILIPE VASCO ; CHARI RAVI ; HUILLE SYLVAIN ; PEREZ RAMIREZ BERNARDO ; BALLET THOMAS</creatorcontrib><description>항-CD38 항체의 제형을 필요로 하는 대상체에게 피하 투여하기에 적합한 항-CD38 항체의 제형이 제공된다. 본 제형은 고농도의 항체, 점도 감소제, 안정화제, 완충제 및 계면활성제를 포함한다. 특정 실시 형태에서, 용액의 점도는 최대 25 mPa·s이고, 용액의 pH는 5.9 내지 7.0이다. 특정 실시 형태에서, 항-CD38 항체는 이사툭시맙(Isatuximab)이다. 제형은 인간에서 다발성 골수종을 비롯한 CD38+ 혈액 악성종양, 및 자가면역 및 염증성 질환을 치료하는 데 사용될 것이다.
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.</description><language>kor</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221205&DB=EPODOC&CC=KR&NR=20220159947A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76289</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20221205&DB=EPODOC&CC=KR&NR=20220159947A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>BANGARI KIRAN</creatorcontrib><creatorcontrib>FILIPE VASCO</creatorcontrib><creatorcontrib>CHARI RAVI</creatorcontrib><creatorcontrib>HUILLE SYLVAIN</creatorcontrib><creatorcontrib>PEREZ RAMIREZ BERNARDO</creatorcontrib><creatorcontrib>BALLET THOMAS</creatorcontrib><title>피하 투여를 위한 항-CD38 항체의 제형</title><description>항-CD38 항체의 제형을 필요로 하는 대상체에게 피하 투여하기에 적합한 항-CD38 항체의 제형이 제공된다. 본 제형은 고농도의 항체, 점도 감소제, 안정화제, 완충제 및 계면활성제를 포함한다. 특정 실시 형태에서, 용액의 점도는 최대 25 mPa·s이고, 용액의 pH는 5.9 내지 7.0이다. 특정 실시 형태에서, 항-CD38 항체는 이사툭시맙(Isatuximab)이다. 제형은 인간에서 다발성 골수종을 비롯한 CD38+ 혈액 악성종양, 및 자가면역 및 염증성 질환을 치료하는 데 사용될 것이다.
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZDB8O2XP26kzFN52rHkzfc3rpXsU3sxpeTt1jsLbqWt1nV2MLUCMN5u2vJk7Q-HNgjlvZ0zlYWBNS8wpTuWF0twMym6uIc4euqkF-fGpxQWJyal5qSXx3kFGBkZGBoamlpYm5o7GxKkCAIXyN_U</recordid><startdate>20221205</startdate><enddate>20221205</enddate><creator>BANGARI KIRAN</creator><creator>FILIPE VASCO</creator><creator>CHARI RAVI</creator><creator>HUILLE SYLVAIN</creator><creator>PEREZ RAMIREZ BERNARDO</creator><creator>BALLET THOMAS</creator><scope>EVB</scope></search><sort><creationdate>20221205</creationdate><title>피하 투여를 위한 항-CD38 항체의 제형</title><author>BANGARI KIRAN ; FILIPE VASCO ; CHARI RAVI ; HUILLE SYLVAIN ; PEREZ RAMIREZ BERNARDO ; BALLET THOMAS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_KR20220159947A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>kor</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>BANGARI KIRAN</creatorcontrib><creatorcontrib>FILIPE VASCO</creatorcontrib><creatorcontrib>CHARI RAVI</creatorcontrib><creatorcontrib>HUILLE SYLVAIN</creatorcontrib><creatorcontrib>PEREZ RAMIREZ BERNARDO</creatorcontrib><creatorcontrib>BALLET THOMAS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>BANGARI KIRAN</au><au>FILIPE VASCO</au><au>CHARI RAVI</au><au>HUILLE SYLVAIN</au><au>PEREZ RAMIREZ BERNARDO</au><au>BALLET THOMAS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>피하 투여를 위한 항-CD38 항체의 제형</title><date>2022-12-05</date><risdate>2022</risdate><abstract>항-CD38 항체의 제형을 필요로 하는 대상체에게 피하 투여하기에 적합한 항-CD38 항체의 제형이 제공된다. 본 제형은 고농도의 항체, 점도 감소제, 안정화제, 완충제 및 계면활성제를 포함한다. 특정 실시 형태에서, 용액의 점도는 최대 25 mPa·s이고, 용액의 pH는 5.9 내지 7.0이다. 특정 실시 형태에서, 항-CD38 항체는 이사툭시맙(Isatuximab)이다. 제형은 인간에서 다발성 골수종을 비롯한 CD38+ 혈액 악성종양, 및 자가면역 및 염증성 질환을 치료하는 데 사용될 것이다.
Provided are formulations of anti-CD38 antibodies suitable for subcutaneous administration to a subject in need thereof. The formulations include a high concentration of antibody, a viscosity lowering agent, a stabilizing agent, a buffering agent and a surfactant. In certain embodiments, the viscosity of the solution is at most 25 mPa·s, and the pH of the solution is 5.9 to 7.0. In certain embodiments, the anti-CD38 antibody is isatuximab. The formulations will find use in treating CD38+ hematological malignancies, including multiple myeloma, as well as autoimmune and inflammatory diseases, in humans.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | kor |
| recordid | cdi_epo_espacenet_KR20220159947A |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | 피하 투여를 위한 항-CD38 항체의 제형 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A23%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=BANGARI%20KIRAN&rft.date=2022-12-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EKR20220159947A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |